Page 10 - Read Online

Ojima. Cancer Drug Resist 2021;4:885-7 https://dx.doi.org/10.20517/cdr.2021.86 Page 887

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
The authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Lyons SK, Plenker D, Trotman LC. Advances in preclinical evaluation of experimental antibody-drug conjugates. Cancer Drug Resist
2021;4:745-54. DOI
2. Venkatesh C, Shen J, Putt KS, Low PS. Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging.
Cancer Drug Resist 2021;4:745-54. DOI
3. Conroy M, Cowzer D, Kolch W, Duffy AG. Emerging RAS-directed therapies for cancer. Cancer Drug Resist 2021;4:543-58. DOI
4. Bijnsdorp IV, Peters GJ. Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro. Cancer
Drug Resist 2021;4:719-27. DOI
5. Giuliani J, Bonetti, A. Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-
line for advanced non-small cell lung cancer. Cancer Drug Resist 2021;4:740-44. DOI